322 PATENT ABSTRACTS

polyamide filtration membranes in the bottom of test wells.

5089394

NEISSERIA DETECTION SYSTEM

Peter K Chun, Albert E Chu assigned to E-Y Laboratories Inc

A specimen containing N. lactamica, N. meningitidis, N. gonorrhoeae or B. catarrhalis is incubated simultaneously with a first substrate for beta-galactosidase and a second substrate for gamma-glutamyl aminopeptidase to form reac- tion products with one or the other Neisseriae which yields a detectible first or second signal distinct from each other depending upon the pre- sence of the enzyme. Signals may comprise dist- inct colors which emit either in the absence or presence of diazo dye coupler. A third substrate specific for prolyliminopeptidase in N. gonorr- hoeae may be added to form a detectible third signal of the same type. The third substrate may be incubated simultaneously with the first two substrates or later. The absence of all of the first three signals is a positive indication that the specimen contains B. catarrhalis. Also, a dia- gnostic test kit for performing the above tests with or without lectin or antibody for agglutina- tion based upon specific recognition.

5091177

MONOCLONAL ANTIBODIES FOR TREATMENT OF HUMAN

NON-SMALL CELL LUNG CARCINOMAS

Ingegerd Hellstrom, Joseph P Brown, Karl E Hellstrom, Diane Horn, Peter Linsley assigned to Oncogen

The present invention is concerned with novel monoclonal antibodies which define a glycolipid antigen associated with human non-small cell lung carcinomas ( NSCLC ) and certain other human carcinomas. The antibodies bind to nor- mal human cells to a much lesser degree than to tumor cells. The antibodies find use in diagnostic methods such as the detection of malignant cells associated with NSCLC and in therapeutic methods. The invention also comprises a method for determining the presence of a malignant con- dition in lung tissue and other human tissue. The method involves examining the human tissue for the presence of a glycolipid antigen having the characteristics of a ganglio-N-triosylceramide.

5991178

TUMOR THERAPY WITH BIOLOGICALLY ACTIVE ANTI-

TUMOR ANTIBODIES

Karl E Hellstrom, Ingeger Hellstrom assigned to Oncogen

A method for identifying and using antibodies which are directed against tumor-associated glycolipid antigens and which are capable of ac- tivating serum complement or antibody depen- dent cellular cytotoxicity. These antibodies find use in the therapy of tumors. Administration of the antibodies results in lysis of the tumor cells in viva.

5091300

RADIO-IMMUNO ASSAY FOR HEPATITIS B VIRUS PRES2

ANTIBODIES

William M Hurni, William Miller assigned to Merck & Co Inc

Anti-hepatitis B virus surface protein (anti- HBS) antibody is adsorbed onto the surface of a substratum. Hepatitis B virus PreSZfS (PreS2+S) protein is then adsorbed onto the same surface through the interaction of the anti- HBS antibody with the S portion of the PreS2 + S protein. The coated surface is then in- cubated concomitantly with the test sample and a radiolabelled antibody specific for the PreS2 portion of the PreS2+ S protein.

5091301

DIAGNOSTIC AND EPIDEMIOLOGICAL NUCLEIC

ACID PROBE FOR BOVINE LEPTOSPIROSIS

Richard L Zuerner assigned to The Unites States of America as represented by the Secretary of Agriculture

A distinctive repetitive genomic element of Lep- tospira interrogans serovar hardjo-type hardjo- bovis permits distinguishing this pathogen type from other commonly found leptospires in North American cattle using single-stranded RNA probes. Plasmids carrying DNA templates for useful probes have been deposited as NRRL